CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
危重癌症患者的免疫治疗：重症监护医生应了解的内容
英文原题：Immunotherapy in the critically ill cancer patient: What the intensivist should know.
查看英文原题
Immunotherapy in the critically ill cancer patient: What the intensivist should know.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫治疗为癌症治疗带来了革命性变革。它通过调控患者的免疫系统来识别并摧毁恶性细胞。近几十年来，这类疗法的开发呈爆发式增长，出现了单克隆抗体和双特异性抗体、免疫检查点抑制剂以及细胞疗法，包括经嵌合抗原受体修饰的T细胞（CAR-T 细胞）和TIL（肿瘤浸润淋巴细胞）。尽管这些新疗法为患者带来了新希望，但它们也带来了由过度活跃的免疫系统作用所引发的新型不良反应谱，如输注反应、自身免疫现象、细胞因子释放综合征、与免疫效应细胞疗法相关的神经毒性，以及毛细血管渗漏综合征。
展开英文摘要原文
Immunotherapy has produced a revolution in the treatment of cancer. It involves manipulating the patient's immune system to identify and destroy malignant cells. There has been an explosion in the development of these therapies in recent decades, with the emergence of monoclonal and bispecific antibodies, immune checkpoint inhibitors, and cellular therapies, including T cells modified with a chimeric antigen receptor (CAR-T cells) and tumor-infiltrating lymphocytes (TILs).
While these new therapies offer new hope to patients, they have also introduced a new profile of adverse effects, resulting from the action of a hyperactive immune system, such as infusion reactions, autoimmune phenomena, cytokine release syndrome, and neurotoxicity associated with immune effector therapies, as well as capillary leak syndrome.
论文信息
- 作者
- Nievas MV、García-Roche A、Jiménez-López M、Díaz-Lagares C
- 单位
- Servicio de Medicina Intensiva, Hospital de la Santa Creu i Sant Pau Barcelona, Barcelona, Spain; Institut de Recerca Sant Pau - Centre CERCA, Barcelona, Spain; Universitat Autonòma Barcelona, Barcelona, Spain. Electronic address: mnievas@santpau.cat.Spain
- 期刊
- Medicina intensiva2026 Sep 9
- 原文标识
- PubMed 42716890 · DOI 10.1016/j.medine.2026.502518